Ginkgo Q4 revenue $33M (-24% YoY); announces biosecurity spin-off, FY2026 cash burn guidance $150-125M

Ginkgo Bioworks Holdings, Inc.

2025-FY EPS reported -$5.64 revenue$170,155,000

Q4 2025 total revenue $33M, down 24% YoY; Cell Engineering $26M (-26%), Biosecurity $7M (-22%).
GAAP net loss $(81)M improved from $(108)M; Adjusted EBITDA $(36)M vs $(57)M.
Full year 2025 revenue $170M (-25%); GAAP net loss $(313)M; Adjusted EBITDA $(167)M; cash $423M.
Announced divestiture of biosecurity business to investor consortium for minority equity stake; expected close H1 2026.
Strategic focus on autonomous labs; decommissioning lab benches; collaborations with OpenAI and PNNL ($47M contract). FY2026 cash burn guidance $(150)-$(125)M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.